Peptide · Fact sheet
Vosoritide
Also known as Voxzogo
Vosoritide is FDA approved as Voxzogo to increase linear growth in children with achondroplasia whose growth plates remain open. It is not approved as a height enhancer for children without achondroplasia or after growth plates close.
What is Vosoritide?
Vosoritide is an analog of C-type natriuretic peptide that counteracts overactive FGFR3 signaling, the central growth-plate mechanism in achondroplasia.
The approval is based on increased annualized growth velocity; final adult height and broader functional outcomes are still being studied.
Benefits & claims
It targets the biology of the most common form of disproportionate short stature rather than supplying growth hormone.
Its accelerated-approval endpoint makes the distinction between faster childhood growth and confirmed long-term clinical benefit important.
What the evidence supports
- The pivotal trial found a greater increase in annualized growth velocity than placebo over one year.
- Extension studies suggest the growth-velocity effect can persist, but confirmatory final-height evidence remains important.
Research areas
- Linear growth in achondroplasia
- Final adult height
- Body proportions and skeletal outcomes
- Function and quality of life in achondroplasia
- Final adult height and broader long-term clinical outcomes
- Other genetically defined skeletal dysplasias
Dosage & frequency
Product-specific label informationVoxzogo is a daily pediatric treatment for achondroplasia with open growth plates. Its amount comes from a weight-band table.
Voxzogo
Pediatric patients with achondroplasia and open epiphyses
- Amount
- Weight-band amounts: 3 kg 0.096 mg; 4 kg 0.12 mg; 5 kg 0.16 mg; 6–7 kg 0.2 mg; 8–11 kg 0.24 mg; 12–16 kg 0.28 mg; 17–21 kg 0.32 mg; 22–32 kg 0.4 mg; 33–43 kg 0.5 mg; 44–59 kg 0.6 mg; 60–89 kg 0.7 mg; ≥90 kg 0.8 mg
- Frequency
- Once daily
- Route studied or labeled
- Subcutaneous
Exact current body-weight band determines the amount.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- The labeled pediatric weight bands should not be replaced with a universal adult dose.
Interactions & precautions
- The label describes low interaction potential in vitro but states that clinical drug-drug interaction studies have not been conducted.
What is still unresolved
- Final adult height and broader long-term functional outcomes remain under study.
Side effects & risks
- The label warns about temporary decreases in blood pressure.
- Common adverse reactions include injection-site reactions, rash, vomiting, joint pain, decreased blood pressure, and gastroenteritis.
- Evidence in some age groups and medical situations is smaller than in the initial pivotal population.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesA randomized Phase 3 trial demonstrated improved annualized growth velocity. Evidence for final adult height and the full set of long-term health and functional outcomes is still developing.
Studies
Pivotal placebo-controlled trial of annualized growth velocity in children with achondroplasia.
Controlled study informing the expanded pediatric indication.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Mood: reported experiences
The emotional burden of treatment
Another parent described considerable emotional difficulty with treatment, despite professional training.
Amount, frequency, route and duration could not be confirmed for this account.
BioMarin funded these interviews. This is a caregiver's experience of treatment burden, not a psychiatric adverse reaction to vosoritide.
Read the original accountsAcceptance improved, while identity concerns remained
Interviewed families described improving acceptance over time; some children worried about losing their identity as a little person.
Amount, frequency, route and duration could not be confirmed for this account.
BioMarin funded these interviews with 15 parents. These are interview themes, not three independent clinical studies. Long-term outcomes were not established.
Read the original accountsGrowth: reported experiences
Small everyday signs of growth
In a parent-interview study, one parent described finding it easier to hold their child's hand while walking, which they interpreted as growth.
Amount, frequency, route and duration could not be confirmed for this account.
BioMarin funded these interviews. This subjective observation from a selected family is not a measured growth result or proof of wider functional benefit.
Read the original accountsApproval status
Voxzogo is FDA approved under accelerated approval to increase linear growth in pediatric patients with achondroplasia and open epiphyses. The FDA later removed its minimum-age restriction.
Approved uses
- Increasing linear growth in pediatric patients with achondroplasia and open growth plates
FDA approved for achondroplasia growth indication
Vosoritide is FDA approved under the Voxzogo label for children with achondroplasia and open growth plates, with accelerated-approval context and follow-up evidence remaining important.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- The magnitude of any change in final adult height
- Long-term effects on function, pain, surgery, body proportions, and quality of life
- Rare harms that may emerge with longer and earlier treatment
- Whether findings extend to skeletal conditions other than achondroplasia
Summary
Vosoritide is a targeted rare-disease peptide with a proven effect on childhood growth velocity. The unresolved question is how that translates into final height and broader long-term outcomes.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Voxzogo
Current indication, accelerated-approval basis, warnings, and adverse reactions.
- fdaFDA: ongoing vosoritide accelerated approval
FDA record of the confirmatory final-adult-height requirement.
- pubmedRandomized Phase 3 vosoritide trial
Pivotal placebo-controlled trial of annualized growth velocity in children with achondroplasia.
- pubmedRandomized trial in children younger than 5
Controlled study informing the expanded pediatric indication.